

SUPPLEMENTARY MATERIAL

References

1. Executive Committee GEMA 2009. GEMA 2009 (Spanish guideline on the management of asthma). *J Investig Allergol Clin Immunol*. 2010;20 Suppl 1:1–59.
2. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. *Rhinology*. 2012;50:1–12.
3. Lildholdt T, Rundcrantz H, Bende M, Larsen K. Glucocorticoid Treatment for Nasal Polyps: The Use of Topical Budesonide Powder, Intramuscular Betamethasone, and Surgical Treatment. *Arch Otolaryngol Head Neck Surg*. 1997;123:595–600.
4. Alobid I, Antón E, Armengot M, Chao J, Colás C, del Cuvillo A et al. SEAIC-SEORL. Consensus Document on Nasal Polyposis. POLINA Project. *J Investig Allergol Clin Immunol*. 2011;21 Suppl 1:1–58.
5. Mansur AH, Srivastava S, Mitchell V, Sullivan J, Kasujee I. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety. *Respir Med*. 2017;124:36–43.
6. Bachert C PD0612: Baseline characteristics of phase 3 randomized controlled trials of omalizumab in chronic rhinosinusitis with nasal polyps. EAACI Congress 2019 Lisbon.
7. Gevaert P, et al. D450: Omalizumab efficacy and safety in nasal polyposis: results from two parallel, double-blind, placebo-controlled trials. ACAAI 2019; Houston, Texas.